One-Pot Three-Component Synthesis of Bispyrazole-thiazole-pyran-2-one Heterocyclic Hybrids

Aicha Saidoun; Leila Boukenna; Yahia Rachedi; Oualid Talhi; Yacine Laichi; Najet Lemouari; Mohamed Trari; Khaldoun Bachari; Artur M.S. Silva

doi:10.1055/s-0037-1610183

Synlett, Table of Contents

Synlett 2018; 29(13): 1776-1780
DOI: 10.1055/s-0037-1610183

letter

One-Pot Three-Component Synthesis of Bispyrazole-thiazole-pyran-2-one Heterocyclic Hybrids

Authors

Aicha Saidoun

^aLaboratoire de Chimie Organique Appliquée, Faculté de Chimie, Université des Sciences et de la Technologie Houari Boumediène, BP 32, El-Alia Bab-Ezzouar, 16111 Alger, Algeria Email: yrachedi@gmail.com
Leila Boukenna

^aLaboratoire de Chimie Organique Appliquée, Faculté de Chimie, Université des Sciences et de la Technologie Houari Boumediène, BP 32, El-Alia Bab-Ezzouar, 16111 Alger, Algeria Email: yrachedi@gmail.com

^bCentre de Recherche Scientifique et Technique en Analyses Physico-Chimiques (CRAPC), BP 384, Bou-Ismail, 42004 Tipaza, Algeria
Yahia Rachedi*

^aLaboratoire de Chimie Organique Appliquée, Faculté de Chimie, Université des Sciences et de la Technologie Houari Boumediène, BP 32, El-Alia Bab-Ezzouar, 16111 Alger, Algeria Email: yrachedi@gmail.com
Oualid Talhi*

^bCentre de Recherche Scientifique et Technique en Analyses Physico-Chimiques (CRAPC), BP 384, Bou-Ismail, 42004 Tipaza, Algeria

^cQOPNA & Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal Email: oualid.talhi@ua.pt Email: artur.silva@ua.pt
Yacine Laichi

^bCentre de Recherche Scientifique et Technique en Analyses Physico-Chimiques (CRAPC), BP 384, Bou-Ismail, 42004 Tipaza, Algeria
Najet Lemouari

^bCentre de Recherche Scientifique et Technique en Analyses Physico-Chimiques (CRAPC), BP 384, Bou-Ismail, 42004 Tipaza, Algeria
Mohamed Trari

^dLaboratoire de Stockage et de Valorisation des Energies Renouvelables, Faculté de Chimie, Université des Sciences et de la Technologie Houari Boumediène BP 32, El-Alia Bab-Ezzouar, 16111 Alger, Algeria
Khaldoun Bachari

^cQOPNA & Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal Email: oualid.talhi@ua.pt Email: artur.silva@ua.pt
Artur M.S. Silva *

^cQOPNA & Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal Email: oualid.talhi@ua.pt Email: artur.silva@ua.pt

Abstract

All articles of this category

Abstract

A new series of some interesting bispyrazole-thiazole-pyran-2-one heterocyclic hybrids has been efficiently synthesized via a one-pot catalyst-free three-component reaction of α-bromoacetylated pyran-2-one derivatives, thiosemicarbazide, and polysubstituted-1-(1H-pyrazol-4-yl)butane-1,3-diones. This multicomponent procedure has been advantageously applied to prepare a structural diversity of heterocyclic hybrids characterized by extensive 1D and 2D NMR spectroscopic studies.

Key words

pyrazoles - thiazoles - pyran-2-ones - chromen-2-ones - three-component synthesis - 1D and 2D NMR

Full Text

References

References and Notes

1a Spino C. Dodier MS. Sotheeswaran S. Bioorg. Med. Chem. Lett. 1998; 8: 3475
1b Basile A. Sorbo S. Spadaro V. Molecules 2009; 14: 939
1c McGlacken GP. Fairlamb IJ. S. Nat. Prod. 2005; 22: 36
1d Lee JS. Mar. Drugs 2015; 13: 1581

2a Egan D. O'Kennedy E. Moran E. Cox D. Prosser E. Thornes RD. Drug Metab. Rev. 1990; 22: 503
2b Hatem AA. Tilal E. Abdullah A. Mohamed IA. Khalid AA. Abdul-Rahman MA. Eur. J. Med. Chem. 2013; 70: 358
2c Starks CM. Russell BW. Norman VL. Rice SM. O’Neil-Johnson M. Lawrence JA. Eldridge GR. Phytochemistry 2014; 98: 216
2d Behrami A. Dobroshi F. J. Chem. Pharm. Res. 2015; 7: 1087
2e Ratnakar RK. Rao SP. Jitender DG. Poornachandra Y. Ganesh KC. Bioorg. Med. Chem. Lett. 2014; 24: 1661
2f Jun M. Bacay AF. Moyer J. Webb A. Carrico-Moniz D. Bioorg. Med. Chem. Lett. 2014; 24: 4654
2g Talhi O. Schnekenburger M. Panning J. Pinto DG. C. Fernandes JA. Paz FA. A. Jacob C. Diederich M. Silva AM. S. Bioorg. Med. Chem. 2014; 22: 3008
2h Veselinović JB. Matejić JS. Veselinović AM. D. Sokolović D. Biol. Nyssana 2016; 7: 167

3a Fahr E. Pharm. Ztg. 1982; 127: 163
3b Altomare C. Perrone G. Zonno MC. Evidente A. Pengue R. Fanti F. Polonelli L. J. Nat. Prod. 2000; 63: 1131
3c Altomare C. Pengue R. Favilla M. Evidente A. Visconti A. J. Agric. Food Chem. 2004; 52: 2997
3d McGlacken GP. Fairlamb I. J. Nat. Prod. Rep. 2005; 22: 369
3e Aiqun L. Xiaoming L. Yuchun F. Tianjiao Z. Qianqun G. Weiming Z. J. Antibiot. 2008; 61: 245

4a Lee S. Park SB. Org. Lett. 2009; 11: 5214
4b Orrego-Hernández J. Cobo J. Portilla J. Eur. J. Org. Chem. 2015; 5064

5a Nasr MN. A. Said SA. Arch. Pharm. 2003; 336: 551
5b Ahasan NB. Rabiul MI. Bangladesh J. Pharm. 2007; 2: 81
5c Shankaraiah N. Devaiah V. Reddy KL. Juvekar A. Sen S. Kurian N. Zingde S. Bioorg. Med. Chem. Lett. 2008; 18: 14681
5d Nadia RM. Nahed YK. Amin FF. Ahmed AE. Der Pharma Chemica 2010; 2: 400
5e Santhosh RM. Sravanthi S. Manjula A. Vittal RaoB. Madhava RB. Sridhar B. Bioorg. Med. Chem. Lett. 2012; 22: 5272

6a Gupta P. Gupta JK. Halve AK. Int. J. Pharm. Sci. Res. 2015; 6: 2291
6b Yu-Ying H. Kimiyoshi K. Hiroyuki T. Masayuki K. Fung FW. Tetrahedron Lett. 2011; 52: 3786
6c Jania DH. Patela HS. Kehariab H. Modic CK. Appl. Organomet. Chem. 2010; 24: 99

7a Sugiura S. Ohno S. Ohtani O. Izumi K. Kitamikado T. Asai H. Kato K. J. Med. Chem. 1977; 20: 80
7b Sakya SM. Rast B. Tetrahedron Lett. 2003; 44: 7629

8a Siddiqui N. Arhad MF. Waquar A. Shamsher AM. Int. J. Pharm. Sci. Drug. Res. 2009; 1: 136
8b Patt WC. Hamilton HW. Taylor MD. Ryan MJ. Taylor DG. J. Connolly CJ. C. Doherty AM. Klutchko SR. Sircar I. Steinbaugh BA. Batley BL. Painchaud CA. Rapundalo ST. Michniewicz BM. Olson SC. J. J. Med. Chem. 1992; 35: 2562
8c Barreca ML. Balzarini J. Chimirri A. De Clercq D. De Luca L. Holtje HD. Holtje M. Monforte AM. Monforte P. Pannecouque C. Rao A. Zappala MJ. J. Med. Chem. 2002; 45: 5410
8d Dinkar M. Chandewar AV. Mahendra RS. Der Chem. Sinica 2011; 2: 137
8e Nepali K. Sharma S. Sharma M. Bedi PM.S. Dhar KL. Eur. J. Med. Chem. 2014; 77: 422

9a Ben Mohamed S. Rachedi Y. Hamdi M. Le Bideau F. Dejean C. Dumas F. Eur. J. Org. Chem. 2016; 2628
9b Bouherou H. Saidoun A. Abderrahmani A. Abdellaziz L. Rachedi Y. Dumas F. Demenceau A. Molecules 2017; 2: 57

10a Rachedi Y. Hamdi M. Speziale V. Synth. Commun. 1989; 19: 3427
10b Aït-baziz N. Rachedi Y. Chemat F. Hamdi M. Asian J. Chem. 2008; 4: 2610

11 Aït-Baziz N. Rachedi Y. Silva AM. S. Arkivoc 2010; (10) : 86
12 Rachedi Y. Hamdi M. Sakellariou R. Spesiale V. Synth. Commun. 1991; 21: 1189

13a Gelin S. Chantegrel B. Nadi A. J. Org. Chem. 1983; 48: 4078
13b Bendaas A. Hamdi M. Sellier N. J. Heterocycl. Chem. 1999; 36: 1291

14a Siddiqui N. Arshad M. Khan S. Acta Pol. Pharm. Drug Res. 2009; 66: 1617
14b Hikem-Oukacha D. Rachedi Y. Hamdi M. Silva AM. S. J. Heterocycl. Chem. 2011; 48: 31

15 General Procedure for the Synthesis of Bispyrazole-thiazole-pyran-2-one Hybrids 13a–d, 14, 15a-c, 15e and 16An equimolar mixture of the appropriate 3-(2-bromoacetyl)-pyran-2-one 10 or 12 (1 mmol), thiosemicarbazide 11 (91 mg, 1 mmol), and diketo-phenylpyrazoles (6a–e or 9, 1 mmol) was heated to reflux in absolute ethanol (10 mL) with vigorous stirring for 30–45 min. After completion of the reaction as indicated by TLC (using a 3:1 mixture of CHCl₃/EtOH as eluent), the products were collected by filtration and then washed with hot ethanol to afford pure products.
16 3-{2-[3′-(4-Chlorophenethyl)-5′-hydroxy-5-methyl-1′-phenyl-1′H,2H-(3,4′-bispyrazol)-2-yl]thiazol-4-yl}-4-hydroxy-6-methyl-2H-pyran-2-one (13b)C₃₀H₂₄ClN₅O₄S, white solid, 0.50 g (85%), mp 299–301 °C. ¹H NMR (400 MHz, DMSO-d ₆): δ = 2.21 (s, 3 H, 6-CH ₃), 2.32 (s, 3 H, 5^b-CH₃), 2.76 (br s, 4 H, H-1^c and H-2^c), 5.97 (s, 1 H, H-5), 6.40 (s, 1 H, H-4^b), 7.00 (d, J = 8.2 Hz, 2 H, H-2′′′,6′′′), 7.08 (d, J = 8.2 Hz, 2 H, H-3′′′,5′′′), 7.28–7.31 (m, 1 H, H-4′′), 7.45–7.49 (m, 2 H, H-3′′,5′′), 7.64–7.66 (m, 2 H, H-2′′,6′′), 7.90 (s, 1 H, H-5^a), 11.53 (s, 1 H, 5′-OH), 12.53 (s, 1 H, 4-OH) ppm. ¹³C NMR (100 MHz, DMSO-d ₆): δ = 13.8 (5^b-CH₃), 19.8 (6-CH₃), 28.4 (C-1^c), 33.2 (C-2^c), 91.5 (C-4′), 94.5 (C-3), 101.1 (C-5), 111.5 (C-5^a), 113.6 (C-4^b), 122.8 (C-2′′,6′′), 126.5 (C-4′′), 128.2 (C-3′′′,5′′′), 129.2 (C-3′′,5′′), 130.4 (C-2′′′,6′′′), 130.8 (C-4′′′), 135.3 (C-3^b), 138.8 (C-1′′), 140.3 (C-1′′′), 144.4 (C-4^a), 149.7 (C-3′), 152.4 (C-5^b), 160.6 (C-2^a), 161.8 (C-2), 162.9 (C-6), 165.1 (C-5′), 168.3 (C-4) ppm. HRMS-ESI⁺: m/z calcd for [C₃₀H₂₄ClN₅O₄S + H]⁺: 586.1310; found: 586.1313.
17 4-Hydroxy-3-{2-[5′-hydroxy-3′,5-dimethyl-1′-phenyl-1′H,2H-(3,4′-bispyrazol)-2-yl]thiazol-4-yl}-6-methyl-2H-pyran-2-one (14)C₂₃H₁₉N₅O₄S, white solid, 0.44 g (95%), mp 235–237 °C. ¹H NMR (400 MHz, DMSO-d ₆): δ = 2.07 (s, 3 H, 3′-CH₃), 2.20 (s, 3 H, 6-CH₃), 2.32 (s, 3 H, 5^b-CH₃), 6.01 (s, 1 H, H-5), 6.49 (s, 1 H, H-4^b), 7.26–7.30 (m, 1 H, H-4′′), 7.44–7.48 (m, 2 H, H-3′′,5′′), 7.66–7.68 (m, 2 H, H-2′′,6′′), 7.94 (s, 1 H, H-5^a), 11.55 (s, 1 H, 5-OH), 12.74 (s, 1 H, 4-OH) ppm. ¹³C NMR (100 MHz, DMSO-d ₆): δ = 13.8 (5^b-CH₃and 3′-CH₃), 19.8 (6-CH₃), 91.8 (C-4′), 94.6 (C-3), 101.1 (C-5), 111.8 (C-5^a), 113.2 (C-4^b), 122.5 (C-2′′,6′′), 126.2 (C-4′′), 129.2 (C-3′′,5′′), 135.7 (C-3^b), 138.9 (C-1′′), 144.4 (C-4^a), 147.1 (C-3′), 152.5 (C-5^b), 160.7 (C-2^a), 161.8 (C-2), 162.9 (C-6), 165.3 (C-5′), 168.5 (C-4) ppm. HRMS-ESI⁺: m/z calcd for [C₂₃H₁₉N₅O₄S + H]⁺: 462.1231; found: 462.1230.
18 3-{2-[5′-Hydroxy-3′-(4-methoxyphenethyl)-5-methyl-1′-phenyl-1′H,2H-(3,4′-bispyrazol)-2-yl]thiazol-4-yl}-2H-chromen-2-one (15e)C₃₄H₂₇N₅O₄S, white solid, 0.36 g (60%), mp 265–267 °C. ¹H NMR (400 MHz, DMSO-d ₆): δ = 2.34 (s, 3 H, 5^b-CH₃), 2.71 (br s, 4 H, H-1^c and H-2^c), 3.51 (s, 3 H, 4′′′-OCH₃), 6.42 (br s, 2 H, H-5 and H-4^b), 6.56 (d, J = 8.5 Hz, 2 H, H-3′′′,5′′′), 6.91 (d, J = 8.4 Hz, H-2′′′,6′′′), 7.06–7.09 (m, 1 H, H-6), 7.28–7.32 (m, 1 H, H-4′′), 7.38–7.40 (m, 1 H, H-8), 7.45–7.49 (m, 2 H, H-3′′,5′′), 7.53–7.57 (m, 1 H, H-7), 7.86–7.88 (m, 2 H, H-2′′,6′′), 7.96 (s, 1 H, H-4), 8.09 (s, 1 H, H-5^a), 11.68 (s, 1 H, 5′-OH) ppm. ¹³C NMR (100 MHz, DMSO-d ₆): δ = 13.9 (5^b-CH₃), 29.7 (C-1^c), 33.2 (C-2^c), 55.1 (4′′′-OCH₃), 92.2 (C-4′), 112.8 (C-4^b), 113.8 (C-3′′′,5′′′), 116.4 (C-8), 116.8 (C-5^a), 119.1 (C-4^a), 120.7 (C-3), 121.2 (C-2′′,6′′), 124.9 (C-6), 125.8 (C-4′′), 128.5 (C-5), 129.5 (C-2′′′,6′′′), 129.6 (C-3′′,5′′), 132.3 (C-7), 133.5 (C-1′′′), 135.3 (C-3^b), 139.3 (C-4), 139.4 (C-1′′), 144.8 (C-4^a), 150.9 (C-3′), 151.7 (C-5^b), 152.8 (C-8^a), 157.7 (C-4′′′), 159.0 (C-2), 160.3 (C-2^a), 161.7 (C-5′) ppm. HRMS-ESI⁺: m/z calcd for [C₃₄H₂₇N₅O₄S + H]⁺: 602.1857; found: 602.1858.
19 3-{2-[5′-Hydroxy-3′,5-dimethyl-1′-phenyl-1′H,2H-(3,4′-bispyrazol)-2-yl]thiazol-4-yl}-2H-chromen-2-one (16)C₂₆H₁₉N₅O₃S, white solid, 0.35 g (72%), mp 248–250 °C. ¹H NMR (400 MHz, DMSO-d ₆): δ = 2.09 (s, 3 H, 3′-CH₃), 2.34 (s, 3 H, 5^b-CH₃), 6.42 (br s, 1 H, H-5), 6.50 (s, 1 H, H-4^b), 7.06–7.10 (m, 1 H, H-6), 7.32 (s, 1 H, H-4′′), 7.37–7.39 (m, 1 H, H-8), 7.47–751 (m, 2 H, H-3′′,5′′), 7.52–7.56 (m, 1 H, H-7), 7.89–7.91 (m, 2 H, H-2′′,6′′), 8.06 (s, 1 H, H-4), 8.11 (s, 1 H, H-5^a), 11.72 (s, 1 H, 5′-OH) ppm. ¹³C NMR (100 MHz, DMSO-d ₆): δ = 13.8 (5^b-CH₃and 3′-CH₃), 91.9 (C-4′), 112.7 (C-4^b), 116.4 (C-8), 116.9 (C-5^a), 119.1 (C-4a), 120.8 (C-3), 121.1 (C-2′′,6′′), 124.9 (C-6), 125.9 (C-4′′), 128.4 (C-5), 129.7 (C-3′′,5′′), 132.4 (C-7), 135.4 (C-3^b), 139.2 (C-4), 139.5 (C-1′′), 144.8 (C-4^a), 149.3 (C-3′), 151.7 (C-5^b), 152.8 (C-8a), 159.0 (C-2), 160.60 (C-2^a), 162.0 (C-5′) ppm. HRMS-ESI⁺: m/z calcd for [C₂₆H₁₉N₅O₃S + H]⁺: 482.1281; found: 482.1274.

Supplementary Material

Supporting Information (PDF) (opens in new window)